Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection

Date: August 26, 2019 Issue #:  1579Summary:  The FDA has approvedDovato (ViiV), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir(Tivicay) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, and generics), as a once-daily complete regimen for treatment of adults with HIV-1 infection who are antiretroviral-treatment naive and have no known substitutions associated with resistance to either drug. Dolutegravir/lamivudine is the first complete regimen to be approved by the FDA for initial treatment of HIV-1 infection that contains 2 rather than 3 antiretroviral drugs.Juluca, a fixed-dose combination of dolutegravir and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine(Edurant), was approved in 2018 for treatment of adults with HIV-1 infection already taking a stable, suppressive antiretroviral regimen.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research